Impurose-A 10 Capsule is a combination pharmaceutical formulation containing Rosuvastatin 10 mg and Aspirin 75 mg, designed to provide dual therapeutic benefits in cardiovascular risk management. Rosuvastatin, a potent HMG-CoA reductase inhibitor, effectively lowers low-density lipoprotein cholesterol (LDL-C) and triglycerides while modestly increasing high-density lipoprotein cholesterol (HDL-C), thereby reducing the risk of atherosclerotic cardiovascular disease. Aspirin, an antiplatelet agent, irreversibly inhibits cyclooxygenase-1 (COX-1), leading to decreased thromboxane A2 production and subsequent inhibition of platelet aggregation, which helps prevent thrombus formation. The combination is indicated for patients at high risk of cardiovascular events such as myocardial infarction, stroke, and peripheral arterial disease, particularly those requiring both lipid-lowering and antiplatelet therapy. Impurose-A 10 Capsule should be administered under medical supervision, with dosage tailored to individual patient needs and risk profiles. Common adverse effects may include gastrointestinal discomfort, myalgia, or bleeding tendencies, necessitating regular monitoring of liver function, lipid profile, and coagulation parameters. This combination therapy offers a convenient and effective approach to comprehensive cardiovascular risk reduction in appropriate patient populations.